Susvimo® (ranibizumab) – New indication
February 4, 2025 - Genentech announced the FDA approval of Susvimo (ranibizumab), for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.
Top